Presenter Dr. Alex Brunelli says neoadjuvant chemoimmunotherapy is a promising and well-tolerated treatment option in select patients with stage III NSCLC. Read more
SABR patients were stable during the 12 months while surgical patients reported clinically significant deterioration at 6 weeks. Read more
Practical aspects of clinically managing operable SABR patients are important for the long-term care of this unique population. Read more
To increase access to radiotherapy worldwide, new guidance from the WHO and IAEA includes a prioritized list of medical devices for cancer management. Read more
Dr. Rodriguez de Dios talks with ILCN about the implications of the PREMER study, a phase III trial comparing PCI with and without hippocampal avoidance in SCLC. Read more
Spine metastases represent a common complication of lung cancer and other cancers, with approximately 40% of patients developing clinically significant spinal metastatic disease and up to 90% developing subclinical micrometastases. […] Read more
A leading cause of mortality worldwide, cancer was tied to nearly 10 million deaths in 2020.1 Lung cancer has remained unchallenged for more than 30 years as the most commonly […] Read more
A 65-year-old patient with stage III NSCLC comes to your clinic to discuss concurrent chemoradiotherapy. She has a history of ischemic heart disease, and 4 years ago an angiogram demonstrated […] Read more
Hippocampal-Sparing Brain Irradiation: The Future of Brain Metastases Treatment and Prevention?
+more
Brain metastases (BMs) are frequently diagnosed in patients with SCLC and NSCLC, although the incidence is highest in SCLC.1 ,2 ,3 BMs are a negative prognostic factor and are associated […] Read more
Prophylactic radiotherapy for the prevention of brain metastases (Table 1) has not been considered a standard practice outside of limited stage SCLC, particularly amid the surge and approval of novel […] Read more